Design, synthesis and antiproliferative activity evaluation of m -(4-morpholinyl-1,3,5-triazin-2-yl)benzamides in vitro
作者： Xiao-Meng Wang , Jing Xu , Min-Hang Xin , She-Min Lu , San-Qi Zhang
DOI: 10.1016/J.BMCL.2015.02.067
关键词:
摘要: Abstract In the present study, a series of m -(4-morpholino-1,3,5-triazin-2-yl)benzamides were designed, synthesized and characterized. Their antiproliferative activities against HCT-116 cell MCF-7 at 10 μM evaluated by MTT assay. Compounds T6 , T10 T11 T12 T19 exhibited potent activities. Thus, their IC 50 values cell, Hela U-87 MG A549 measured. The SAR target compounds was preliminary discussed. Western bolt assay suggested that compound can block PI3K/Akt/mTOR pathway. Hoechst staining indicated cause morphological changes induce apoptosis cells. These findings directly identify -(4-morpholinyl-1,3,5-triazin-2-yl)benzamide derivatives as novel agents further verify value benzamide fragment in drug design.
elsevier.com
sci-hub.se 参考文章(21)
Teng Shao, Juan Wang, Jian-Gang Chen, Xiao-Meng Wang, Huan Li, Yi-Ping Li, Yan Li, Guang-De Yang, Qi-Bing Mei, San-Qi Zhang, Discovery of 2-methoxy-3-phenylsulfonamino-5-(quinazolin-6-yl or quinolin-6-yl)benzamides as novel PI3K inhibitors and anticancer agents by bioisostere. European Journal of Medicinal Chemistry. ,vol. 75, pp. 96- 105 ,(2014) , 10.1016/J.EJMECH.2014.01.053
Xiao-Meng Wang, Jing Xu, Yi-Ping Li, Huan Li, Cong-Shan Jiang, Guang-De Yang, She-Min Lu, San-Qi Zhang, Synthesis and anticancer activity evaluation of a series of [1,2,4]triazolo[1,5-a]pyridinylpyridines in vitro and in vivo. European Journal of Medicinal Chemistry. ,vol. 67, pp. 243- 251 ,(2013) , 10.1016/J.EJMECH.2013.06.052
Pixu Liu, Hailing Cheng, Thomas M. Roberts, Jean J. Zhao, Targeting the phosphoinositide 3-kinase pathway in cancer Nature Reviews Drug Discovery. ,vol. 8, pp. 627- 644 ,(2009) , 10.1038/NRD2926
Nobuko Nishimura, Aaron Siegmund, Longbin Liu, Kevin Yang, Marian C. Bryan, Kristin L. Andrews, Yunxin Bo, Shon K. Booker, Sean Caenepeel, Daniel Freeman, Hongyu Liao, John McCarter, Erin L. Mullady, Tisha San Miguel, Raju Subramanian, Nuria Tamayo, Ling Wang, Douglas A. Whittington, Leeanne Zalameda, Nancy Zhang, Paul E. Hughes, Mark H. Norman, Phospshoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: discovery and structure-activity relationships of a series of quinoline and quinoxaline derivatives. Journal of Medicinal Chemistry. ,vol. 54, pp. 4735- 4751 ,(2011) , 10.1021/JM200386S
Gordon W Rewcastle, Swarna A Gamage, Jack U Flanagan, Raphael Frederick, William A Denny, Bruce C Baguley, Philip Kestell, Ripudaman Singh, Jackie D Kendall, Elaine S Marshall, Claire L Lill, Woo-Jeong Lee, Sharada Kolekar, Christina M Buchanan, Stephen MF Jamieson, Peter R Shepherd, None, Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474). Journal of Medicinal Chemistry. ,vol. 54, pp. 7105- 7126 ,(2011) , 10.1021/JM200688Y
Yanlong Zhao, Xi Zhang, Yingyi Chen, Shaoyong Lu, Yuefeng Peng, Xiang Wang, Chengliang Guo, Aiwu Zhou, Jingmiao Zhang, Yu Luo, QianCheng Shen, Jian Ding, Linghua Meng, Jian Zhang, Crystal Structures of PI3Kα Complexed with PI103 and Its Derivatives: New Directions for Inhibitors Design ACS Medicinal Chemistry Letters. ,vol. 5, pp. 138- 142 ,(2014) , 10.1021/ML400378E
Daniel P. Sutherlin, Linda Bao, Megan Berry, Georgette Castanedo, Irina Chuckowree, Jenna Dotson, Adrian Folks, Lori Friedman, Richard Goldsmith, Janet Gunzner, Timothy Heffron, John Lesnick, Cristina Lewis, Simon Mathieu, Jeremy Murray, Jim Nonomiya, Jodie Pang, Niel Pegg, Wei Wei Prior, Lionel Rouge, Laurent Salphati, Deepak Sampath, Qingping Tian, Vickie Tsui, Nan Chi Wan, Shumei Wang, BinQing Wei, Christian Wiesmann, Ping Wu, Bing-Yan Zhu, Alan Olivero, Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer Journal of Medicinal Chemistry. ,vol. 54, pp. 7579- 7587 ,(2011) , 10.1021/JM2009327
Jeffrey A. Engelman, Ji Luo, Lewis C. Cantley, The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism Nature Reviews Genetics. ,vol. 7, pp. 606- 619 ,(2006) , 10.1038/NRG1879
Huan Li, Xiao-Meng Wang, Juan Wang, Teng Shao, Yi-Ping Li, Qi-Bing Mei, She-Min Lu, San-Qi Zhang, Combination of 2-methoxy-3-phenylsulfonylaminobenzamide and 2-aminobenzothiazole to discover novel anticancer agents. Bioorganic & Medicinal Chemistry. ,vol. 22, pp. 3739- 3748 ,(2014) , 10.1016/J.BMC.2014.04.064
Noel D D’Angelo, Tae-Seong Kim, Kristin Andrews, Shon K Booker, Sean Caenepeel, Kui Chen, Derin D’Amico, Dan Freeman, Jian Jiang, Longbin Liu, John D McCarter, Tisha San Miguel, Erin L Mullady, Michael Schrag, Raju Subramanian, Jin Tang, Robert C Wahl, Ling Wang, Douglas A Whittington, Tian Wu, Ning Xi, Yang Xu, Peter Yakowec, Kevin Yang, Leeanne P Zalameda, Nancy Zhang, Paul Hughes, Mark H Norman, None, Discovery and Optimization of a Series of Benzothiazole Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors Journal of Medicinal Chemistry. ,vol. 54, pp. 1789- 1811 ,(2011) , 10.1021/JM1014605